UA48700A - Method for treating eczema of bacterial origin - Google Patents

Abstract

The method for treating the eczema of bacterial origin comprises employing infusion solutions, in particular Reosorbilact. The solution (200-400 ml) is administered intravenously once a day for the first three days then once in three days, 5-10 infusions in total.

Description

Description of the invention

The invention relates to the field of medicine, in particular to dermatology and can be used in complex 2 therapy of microbial eczema.

The method of treatment of microbial eczema (V.F. Orkin, N.M. Olekhnovich, T.A Rassoha, etc.) was chosen as a prototype.

A method of treating patients with microbial infection with intravenous sodium hypochlorite infusions./ /Russian Journal of Skin and Venereal Diseases. - 2000. - Mo3. - P.31 - 33), which consists in the fact that patients with microbial eczema are prescribed therapy, which includes antibacterial, antihistamine, hyposensitizing, vitamin preparations and an infusion preparation - 0.3395 sodium hypochlorite solution of 20 mol, intravenously, slowly, for 10 - 15 days.

Features that coincide with the essential features of the claimed method are: use of solutions from the group of infusion drugs.

The technical result of the proposed invention is an increase in the effectiveness of treatment with a minimum of 72 side effects.

The reasons preventing the achievement of the expected technical result are: allergic reactions in the form of general and local manifestations that occur when using sodium hypochlorite; the occurrence of thrombophlebitis of deep veins, as well as the fact that sodium hypochlorite is obtained by electrolysis of an isotonic solution of sodium chloride 0.8995 in the EDO-4 apparatus, which greatly limits the availability and breadth of use of this medicinal product.

The basis of the invention is the task of improving the method of treating microbial eczema by replacing the infusion drug with a new one that has a complex effect, does not cause a number of side effects and affects many organs and systems of the body, which allows to achieve the expected technical result.

The task is solved by the fact that in the method of treating microbial eczema, which includes the use of solutions from the group of infusion drugs, according to the invention, as an infusion drug, Reosorbilact is used, which is administered intravenously at 200 - 40 Omol, in the first three days - daily, then 1 once in

From days, a course of 5 - 10 infusions.

Between the set of essential features of the proposed invention and the expected technical result, the following cause-and-effect relationship is manifested: the use of the drug Reosorbilact, which has a multidirectional effect, which manifests itself in the form of anti-inflammatory, immunomodulating, detoxification, Ha") antioxidant effects, contributes to the rapid regression of skin process and reduction of treatment terms; and also makes it possible to increase the effectiveness of general therapy, which, in turn, reduces the duration of taking medicinal products; intravenous infusions are widely used medical manipulations, for the implementation of the method no special technical equipment and training of medical personnel is required; 3 o the proposed drug Reosorbilact is produced in Ukraine and has a relatively affordable cost, which also determines the economic feasibility of the proposed method; in the absence of the above-listed signs, the technical result is unattainable.

The main pharmacologically active substances of Reosorbilact are sorbitol and sodium lactate - in an isotonic "concentration, sorbitol is quickly included in the general metabolism, 80 - 9095 of sorbitol is utilized in the liver and - 70 is accumulated in the form of glycogen, 595 is deposited in the tissues of the brain, heart muscle and striated with muscles, 6 - 1295 is excreted in the urine. In the liver, sorbitol is first converted into fructose, which is then converted into glucose, and then into glycogen, part of sorbitol is used for cardiac energy needs. The active part of the lactate solution is considered to be only half of it - isomer I, and the other half - isomer O is not metabolized and is excreted in the urine.

The drug was developed by the Lviv Research Institute of Blood Pathology and Transfusion Medicine, approved for use by the Ministry of Health of Ukraine, registration certificate MoR.04.00//01611 dated 04.04.00. It is possible to use a small one

Ge | amount of solution - up to 400 mol, without control of blood osmolality and acid-base status.

Information that confirms the possibility of using the invention: and 72 patients with microbial eczema were under observation, of which 30 were men and 42 were women, the age of the patients was av! 20 to 76 years old. The duration of the disease is from 1 year to 16 years. The patients who made up the main group - 72 people - were treated in the proposed way. The comparison group consisted of 67 patients with microbial eczema, who were close to the main group in terms of gender, age, and duration of the disease. Patients from the comparison group were treated according to the prototype method.

The criterion for evaluating the therapeutic effectiveness of Reosorbilact is the improvement of the general well-being of 29 patients, cessation of itching, resolution of clinical signs of microbial eczema. A number of laboratory in indicators: the level of circulating immune complexes, the level of molecules of average mass in blood serum and urine.

The state of lipid peroxidation was assessed in the reaction with thiobarbituric acid, the state of the antioxidant system was assessed by the level of superoxide dismutase and ceruloplasmin. The resulting digital material will be subjected to statistical processing with the calculation of the Student's probability index. 60 In the table Mo1 shows the dynamics of laboratory indicators in patients with microbial eczema during treatment, where

CPS - circulating immune complexes; TBK - thiobarbituric acid, CP - ceruloplasmin, SOD - superoxide dismutase, MSM - medium mass molecules.

As a result of the application of the proposed method of treatment of microbial eczema, the studied laboratory parameters were normalized. In the patients of the main group, the regression of clinical signs of dermatosis was much faster than in the patients of the comparison groups. The duration of inpatient treatment was: main group 17.0 x 2.3 days; in the comparison group, 22.7 x 1.4 days. It should be noted that the tolerance of Reosorbilact in all patients was good, allergic reactions, side effects and complications of local and general level were not observed. The final results of treatment in patients of the main group: clinical recovery - 26 people, which amounted to 3690; a significant improvement of the Great Danes of 32 people, which amounted to 4495; moderate improvement - 10 people, which amounted to 1495; weak deterioration - 4 people who made a bean.

The method is as follows.

After the diagnosis of microbial eczema is made, patients are given traditional therapy - antihistamine, antibacterial, hyposensitizing, vitamin preparations and Reosorbilact is prescribed 200 - 400 mol, 7/0 Intravenous, drip, in the first 3 days daily, then once in 3 days, for a course of 5 - 10 infusions. The duration and volume of therapy are determined individually, taking into account the general condition, the presence of concomitant pathology, the prevalence and severity of clinical signs of dermatosis.

For example, to patients with microbial eczema, in which no more than 3095 skins are affected, the general condition is not disturbed and there is no severe pathology on the part of internal organs, on the background of therapy, the drug Reosorbilact is prescribed according to /5 the following scheme: 200 mol, intravenously, drip, in the first Z days - daily, then 2 more infusions with an interval of 1 time in 3 days, for a course - 5 infusions.

Patients with microbial eczema, in which up to 7095 skin is affected, there are signs of a general condition disorder and functional pathology of internal organs and systems, the drug Reosorbilact is prescribed according to the following scheme: 40 Omol, intravenously, drip, in the first 3 days - daily, then another 2 - From infusion with an interval of 1 time in 3 days, for a course of 5 - 6 infusions.

In patients with microbial eczema, in which more than 7095 skins are affected, there is a medium and severe degree of severity of the general condition, as well as morphofunctional insufficiency of internal organs and systems, Reosorbilact is prescribed according to the following scheme: 400 ml, intravenously, drip, in the first 3-4 days daily, then every other day, for a course of 7 - 10 infusions.

The method is confirmed by the following examples of its implementation.

Example 1. "

Patient S. - 67 years old, medical history Mo953.

Diagnosis: chronic paratraumatic microbial eczema.

History of the disease: sick for 2 years, the onset of the disease is associated with an injury to the lower limb, relapses occur 2 - 3 times a year, underwent courses of outpatient and inpatient treatment - without significant effect. In connection with another exacerbation, she was hospitalized. at

Life history: grew and developed according to age. Skin diseases are not burdened by heredity. M

Allergic reactions to products and medicines were not observed. There are no bad habits. At the age of 49, she underwent an appendectomy. For 20 years, he has been registered with a gastroenterologist for chronic enterocolitis. co

Upon admission to the hospital: the general condition is satisfactory, the physique is correct, the nutrition is increased. "Mr

Complaints about a rash in the area of the left lower leg, sputum, itching in the area of the rash. Body temperature is 36.8". The skin is free from rashes of the usual color. Peripheral lymph nodes are free of pathology. Internal organs and systems are without visible changes. Special status: the dermatosis is organic in nature, localized on the skin of the lower leg of the left leg. There is a focus of hyperemia with clear borders, moderately infiltrated, "eroded elements on the surface, purulent crusts, purulent discharge, sputum phenomena. z c In the hospital, the patient was examined: leukocytosis, increased ESR, increased indicators of lipid peroxidation and endogenous intoxication were found. Given the low effectiveness of the previously carried out therapy in ;" complex treatment, in addition to antibacterial, antihistaminic, generally strengthening, vitamin preparations and local therapy, the patient is prescribed Reosorbilact 200 ml, intravenous, drip, the first 3 days daily, then 2 more infusions with an interval of 1 time on the 3rd day, for a course of 5 infusions. during the 12-day course of treatment, the patient's skin process was almost completely resolved, itching disappeared and laboratory parameters normalized. Example 2. - Patient K. - 59 years old, medical history Mo862.

Diagnosis: chronic microbial eczema, stage of exacerbation. The state of erythroderma. o History of the disease: sick for about 7 years, at first the process was localized on the skin of both lower legs, then o took on a widespread nature. Recurrences of the disease are observed 3 - 4 times a year, 2 - 3 times a year he undergoes courses of inpatient treatment, but a stable and long-term remission does not occur. The last exacerbation is associated with nervous overstrain.

Life history: grew and developed according to age. Among the transferred diseases, he notes: Botkin's disease.

Heredity is not burdened. There were no injuries or operations. On the register with a therapist for chronic hepatitis and

P" of gastroduodenitis, at the surgeon's office for varicose veins of the lower extremities.

Upon admission to the hospital: general condition of moderate severity, correct physique, reduced nutrition. 60 Complaints of general weakness, malaise, rashes all over the body, severe itching. Body temperature is 38.27"C. Peripheral lymph nodes are enlarged, the size of a cherry stone, dense-elastic consistency, moderately painful. Vesicular breathing in the lungs. Heart sounds are clear, rhythmic P - 96 per minute, blood pressure - 150/10Omm.Hg .

Special status: dermatosis affects the skin of the trunk, upper and lower limbs and is characterized as 65 erythroderma. On the skin of both lower legs, there are slightly congested and hypermeasurable foci, infiltrated, erosive-ulcerative elements on the surface, 0.3 - 0.5 cm deep, purulent exudate, layering of purulent crusts, the varicose symptom complex of the veins of the lower extremities is determined. On the skin of the trunk and upper limbs, a spotted erythematous-squamous rash is noted, the spots rise above the skin level, the borders are sharp, the edges are scalloped.

Laboratory examination data: leukocytosis with a shift to the left, sharp fading of ESR, ALT, AST.

Increased level of markers of endogenous intoxication - molecules of medium weight, higher than normal indicators of lipid peroxidation.

The patient was prescribed: broad-spectrum antibacterial drugs, antihistaminic and hyposensitizing drugs, non-steroidal anti-inflammatory drugs and Reosorbilact 400 ml, intravenously, drip, daily for the first 4 days, then Z infusion with an interval of 1 day and another Z infusion with an interval of 2 days, for a course of 10 infusions. 70 In the course of the therapy, on the 3rd day, the general condition and body temperature normalized, positive dynamics of eczema symptoms were observed. By the end of the treatment, the course of which was 21 days, the rash on the skin of the trunk and upper limbs was completely resolved, the skin of the lower legs underwent complete epvtelvzatsvya erosion, the itching regressed, areas of hyperpigmentation and foci of weak infiltration remained as residual effects. The values of laboratory indicators have come as close as possible to normal values.

The obtained results are convincing evidence of the effectiveness of the proposed method of treating microbial eczema, which allows recommending it for widespread distribution and use in dermatological practice.

Table 1

METHOD OF TREATMENT OF MICROBIAL ECZEMA

Indicator) Control n - 18 Main group n - 72 Comparison group n - 67

Tsik, d. unit 22330 364 22.1 x 1.0 ZT x 3.3 29.7 x 0.8"

TBK products (nmol MDA/mol) 18258.28 211.37 (4.84) 183.06 7.617 213.21 - 541 196.4 (2.83" 159.12 x 18.47) 119.04 (k 19, 74 157.38 x 15.72") 118.09 x 12.55. 130.05 to 6.067

SOD, d. units) 364.94 x 35.47| 202.08 x 24.68) 365.69 x 21.18") 204.16 x 2.92) 329.19 x 12.08"

IOM in blood serum, um. from 0.246 - 0.001 0.350 0.9 0.251 0.001" 0.358 - 0.008 0.294 and 0.037 "

IOM in urine, um. unit 39103 ZBBzhO01 4O,Z w 0.3" ZbO0vo04 38.1 02

Note: Asterisk - significant differences (p"0.05; 0.01; 0.001) of indicators between the main group and the comparison group "c) then o

Claims (1)

The formula of the invention in the Method of treatment of microbial eczema, which includes the use of solutions from the group of infusion drugs, (ee) which differs in that Reosorbilact is used as an infusion drug, which is administered intravenously "at 200-400 ml, in the first 3 days - daily, then 1 time in 3 days, a course of 5-10 infusions. Official bulletin "Industrial Property". Book 1 "Inventions, useful models, topographies of integrated microcircuits", 2002, M 8, 15.08.2002. State Department of Intellectual Property of the Ministry of Education and Science of Ukraine. 400 Muky Ukr - . and? ChK" (ee) -i ("c) (42) 60 b5